Humoral and cellular response of two different vaccines against SARS-CoV-2 in a group of healthcare workers: An observational study

• Published in: Journal of immunological methods Vol. 528; p. 113665
• Main Authors: Stambouli, Nejla, Bahrini, Khadija, Romdhani, Chihebeddine, Rebai, Aicha, Boughariou, Sana, Zakraoui, Mohamed, Arfaoui, Bilel, Seyli, Sameh, Boukhalfa, Yasmine, Battikh, Riadh, Moussa, Mohamed Ben, Labbene, Iheb, Ferjani, Mustpha, Gharssallah, Hedi
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01-05-2024
• Subjects: Adenovirus Vaccines; Antibodies, Neutralizing; Antibodies, Viral; Blood Group Antigens; Cellular response,vaccination; COVID-19; COVID-19 Vaccines; Health Personnel; Humans; Humoral responses; Immunity, Humoral; Interferon-gamma; mRNA Vaccines; Pfizer BioNTech; SARS-CoV-2; Sputnik-Gameleya V; Vaccination; Vaccines; INF; Pfizer BioNTech; Sputnik-Gameleya V; Humoral responses; Cellular response,vaccination; QFN; IQR; HCW; NAB; IGRA; ELISA
• DOI: 10.1016/j.jim.2024.113665
• EISSN: 1872-7905
• ISSN: 0022-1759; 1872-7905

On March 13, 2021, Tunisia started a widespread immunization program against SARS-CoV-2 utilizing different vaccinations that had been given emergency approval. Herein, we followed prospectively a cohort of participant who received COVID-19 vaccine (Pfizer BioNTech and Sputnik-Gameleya V). The goal of this follow-up was to define the humoral and cellular immunological profile after immunization by assessing neutralizing antibodies and IFN- γ release. 26 vaccinated health care workers by Pfizer BioNTech (n=12) and Sputnik-Gameleya V (n=14) were enrolled from June to December 2021 in Military hospital of Tunis. All consenting participants were sampled for peripheral blood after three weeks of vaccination. The humoral response was investigated by the titer of anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies to S1 protein. The CD4 and CD8 T cell responses were evaluated by the QuantiFERON® SARS-CoV-2 (Qiagen® Basel, Switzerland).
Regardless the type of vaccine, the assessment of humoral and cellular response following vaccination showed a strong involvement of the later with expression of IFN-γ as compared to antibodies secretion. Moreover, we showed that people with past SARS-CoV-2 infection developed high levels of antibodies than those who are not previously infected. However, no significant difference was detected concerning interferon gamma (IFN-γ) expression by CD4 and CD8 T cells in health care worker (HCW) previously infection or not with COVID-19 infection. Analysis of immune response according to the type of vaccine, we found that Pfizer BioNTech induced high level of humoral response (91.66%) followed by Sputnik-Gameleya V (64.28%). However, adenovirus vaccine gave a better cellular response (57.14%) than mRNA vaccine (41.66%). Regarding the immune response following vaccine doses, we revealed a significant increase of neutralizing antibodies and IFN-γ release by T cells in patients fully vaccinated as compared to those who have received just one vaccine.
Collectively, our data revealed a similar immune response between Pfizer BioNTech and Sputnik-Gameleya V vaccine with a slight increase of humoral response by mRNA vaccine and cellular response by adenovirus vaccine. It's evident that past SARS-CoV-2 infection was a factor that contributed to the vaccination's increased immunogenicity. However, the administration of full doses of vaccines (Pfizer BioNTech or Sputnik-Gameleya V) induces better humoral and cellular responses detectable even more than three months following vaccination.